RESUMO
Fruit maturity at harvest is a major factor in determining its quality. In this study, external skin color of grape has been utilized to predict their chemical content and, in turn, the maturity of the fruit. Measurements of the chemical content such as Brix and acidity were made on ten bunches of "Shine Muscat" grapes at three different harvest periods (immature, mature, and overmature). Using a machine vision system, color and UV-excited fluorescence images of grape berries and bunches were taken during the respective harvest stages. Acquired images were processed using ImageJ to obtain RGB values. Rratio and a*/b* are strongly related to Brix and sugar-to-acid ratio of grape fruit, with regression coefficients of 0.5626 and 0.5180, repectively. It was found that a* color index was the best predictor of grape bunch maturity. Furthermore, discriminant analysis has shown that color images of grape berries perform better than 365 nm fluorescence images.
RESUMO
BACKGROUND: The FDA approval of oncolytic herpes simplex-1 virus (oHSV) therapy underscores its therapeutic promise and safety as a cancer immunotherapy. Despite this promise, the current efficacy of oHSV is significantly limited to a small subset of patients largely due to the resistance in tumor and tumor microenvironment (TME). METHODS: RNA sequencing (RNA-Seq) was used to identify molecular targets of oHSV resistance. Intracranial human and murine glioma or breast cancer brain metastasis (BCBM) tumor-bearing mouse models were employed to elucidate the mechanism underlying oHSV therapy-induced resistance. RESULTS: Transcriptome analysis identified IGF2 as one of the top secreted proteins following oHSV treatment. Moreover, IGF2 expression was significantly upregulated in 10 out of 14 recurrent GBM patients after treatment with oHSV, rQNestin34.5v.2 (71.4%) (p=0.0020) (ClinicalTrials.gov, NCT03152318). Depletion of IGF2 substantially enhanced oHSV-mediated tumor cell killing in vitro and improved survival of mice bearing BCBM tumors in vivo. To mitigate the oHSV-induced IGF2 in the TME, we constructed a novel oHSV, oHSV-D11mt, secreting a modified IGF2R domain 11 (IGF2RD11mt) that acts as IGF2 decoy receptor. Selective blocking of IGF2 by IGF2RD11mt significantly increased cytotoxicity, reduced oHSV-induced neutrophils/PMN-MDSCs infiltration, and reduced secretion of immune suppressive/proangiogenic cytokines, while increased CD8+cytotoxic T lymphocytes (CTLs) infiltration, leading to enhanced survival in GBM or BCBM tumor-bearing mice. CONCLUSION: This is the first study reporting that oHSV-induced secreted IGF2 exerts a critical role in resistance to oHSV therapy, which can be overcome by oHSV-D11mt as a promising therapeutic advance for enhanced viro-immunotherapy.